These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation? Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078 [TBL] [Abstract][Full Text] [Related]
9. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation. Doshi N; Martin J; Tomlinson A Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040 [TBL] [Abstract][Full Text] [Related]
10. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material. Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966 [TBL] [Abstract][Full Text] [Related]
11. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics. Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888 [TBL] [Abstract][Full Text] [Related]
12. Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions. Doshi N; Rutherford K; Najjar A J Pharm Sci; 2021 Feb; 110(2):687-692. PubMed ID: 33039438 [TBL] [Abstract][Full Text] [Related]
13. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation. Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486 [TBL] [Abstract][Full Text] [Related]
14. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations. Doshi N; Demeule B; Yadav S Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285 [TBL] [Abstract][Full Text] [Related]
15. Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations. Pegues MA; Szczepanek K; Sheikh F; Thacker SG; Aryal B; Ghorab MK; Wolfgang S; Donnelly RP; Verthelyi D; Rao VA Pharm Res; 2021 Nov; 38(11):1961-1975. PubMed ID: 34845573 [TBL] [Abstract][Full Text] [Related]
16. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies. Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038 [TBL] [Abstract][Full Text] [Related]
17. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80. Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015 [TBL] [Abstract][Full Text] [Related]
18. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism. Tomlinson A; Demeule B; Lin B; Yadav S Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339 [TBL] [Abstract][Full Text] [Related]
19. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time. Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968 [TBL] [Abstract][Full Text] [Related]
20. Extended Characterization and Impact of Visible Fatty Acid Particles - A Case Study With a mAb Product. Saggu M; Demeule B; Jiang L; Kammerer D; Nayak PK; Tai M; Xiao N; Tomlinson A J Pharm Sci; 2021 Mar; 110(3):1093-1102. PubMed ID: 33271136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]